Latest Stories from Cancer Promoted Stories,2015-04-13:/category/medical/cancer2015-04-13T06:48:41-07:00<![CDATA[Genzyme to Present New Long-Term Data on Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) at AAN]]>,2015-04-13:3669392015-04-13T06:05:42-07:00logo

– 30 Presentations Planned On Marketed Products and New Data from Company’s MS Pipeline – ]]>
<![CDATA[Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2015 Financial Results on April 30, 2015]]>,2015-04-13:3606912015-04-13T06:01:32-07:00logo

<![CDATA[UK’s Aintree University Hospital Joins CEL-SCI’s Phase III Head and Neck Cancer Trial]]>,2015-04-13:3659072015-04-13T05:38:08-07:00logo

<![CDATA[Cologuard® Receives Coverage by Several Commercial Health Plans in Q1 2015]]>,2015-04-13:3551832015-04-13T05:05:59-07:00logo

Exact Sciences announces expanded patient access to Cologuard as a result of several insurers now covering the test. Cologuard is now covered for more than 90 million lives across the U.S.]]>
<![CDATA[Paolo Paoletti, M.D., Named To FORMA Therapeutics Board of Directors]]>,2015-04-13:3630212015-04-13T05:04:08-07:00logo

FORMA appointed Paolo Paoletti, M.D., to its Board of Directors. He will also lead FORMA's Research & Development Committee as its chairperson. Dr. Paoletti was previously President of GSK Oncology.]]>
<![CDATA[Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells and Impedes Resistance to Anti-angiogenic Therapy in Preclinical Models]]>,2015-04-13:3688242015-04-13T04:10:09-07:00logo

Cerulean today announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101 targets breast cancer stem cells.]]>
<![CDATA[Blend Therapeutics Appoints Drew Fromkin as President and Chief Executive Officer]]>,2015-04-13:3681152015-04-13T04:01:59-07:00logo

Company to Accelerate Development of Cancer Product Pipeline, with Filing of IND for Lead Product Candidate in Q2 2015 ]]>
<![CDATA[IOmet Pharma Demonstrates Superior in Vivo PK/PD Properties in Pre-Clinical IDO1, TDO and Dual IDO1/TDO Cancer Immunotherapy Programs]]>,2015-04-12:3555862015-04-12T22:00:09-07:00logo

Data to Be Presented April 22 at American Association for Cancer Research 2015 Annual Meeting ]]>
<![CDATA[Cerulean Closes Public Offering of Common Stock]]>,2015-04-10:3597852015-04-10T06:31:08-07:00logo

Underwriters fully exercise option to purchase additional shares ]]>
<![CDATA[Dicerna Presents New β-catenin Data from Multiple Tumor Models at the 2015 RNA & Oligonucleotide Therapeutics Meeting at Cold Spring Harbor Laboratory]]>,2015-04-10:3603362015-04-10T05:02:03-07:00logo

Data Show Robust Silencing of CTNNB1 Gene in Patient-Derived Xenograft and Other Cancer Models Using RNAi ]]>
<![CDATA[New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015]]>,2015-04-10:3713682015-04-10T05:01:22-07:00logo

New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015]]>
<![CDATA[Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015]]>,2015-04-09:3726572015-04-09T14:05:21-07:00logo

- Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT - ]]>
<![CDATA[Rosetta Genomics to Acquire PersonalizeDx]]>,2015-04-09:3649472015-04-09T09:16:02-07:00logo

Creates a broader commercial footprint and expanded product offering in oncology diagnostics with numerous near-term product launches to accelerate revenue growth Enhances Rosetta Genomics’ leadership as a provider of proprietary and differentiated content in the personalized medicine arena Rosetta Genomics expects annualized pro forma 2015 revenues of $10 million to $12 million, and 2016 revenues to exceed $18 million ]]>
<![CDATA[MEDIAN Announces the Award of New Medical Image Interpretation and Management Projects for Clinical Trials for a Total of €2.76M]]>,2015-04-09:3688152015-04-09T09:00:15-07:00logo

Award* of three Phase II projects sponsored by two major American biotech companies specializing in oncology ]]>
<![CDATA[Helomics™ to Present at the Personalized Medicine World Conference in Oxford, England]]>,2015-04-09:3606662015-04-09T07:02:02-07:00logo

Helomics’ to Present an Overview of its Personalized Comprehensive Tumor Profiling Platform ]]>